Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 12, 2011 - Issue 13
Submit an article Journal homepage
333
Views
5
CrossRef citations to date
0
Altmetric
Reviews

New therapies for castrate-resistant prostate cancer

Stephen B Williams Brigham and Women's Hospital, Harvard Medical School, Division of Urology, 75 Francis Street, Boston, MA 02115, USA+1 617 732 6325; +1 617 566 3475; [email protected]
, MD,
Aaron H Lay Brigham and Women's Hospital, Harvard Medical School, Division of Urology, 75 Francis Street, Boston, MA 02115, USA+1 617 732 6325; +1 617 566 3475; [email protected]
,
Clayton S Lau City of Hope Comprehensive Cancer Centre, Division of Urologic Oncology, Department of Urology, Duarte, CA 91010, USA
,
David Y Josephson City of Hope Comprehensive Cancer Centre, Division of Urologic Oncology, Department of Urology, Duarte, CA 91010, USA
,
Timothy G Wilson City of Hope Comprehensive Cancer Centre, Division of Urologic Oncology, Department of Urology, Duarte, CA 91010, USA
,
Toni K ChoueiriDana-Farber Cancer Institute, Harvard Medical School, Lank Center for Genitourinary Oncology, Boston, MA 02115, USA
&
Sumanta K Pal City of Hope Comprehensive Cancer Centre, Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, Duarte, CA 91010, USA
 show all
Pages 2069-2074 | Published online: 11 Jun 2011
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Introduction: Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies.

Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents.

Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

Notes

This box summarizes key points contained in the article.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.